Literature DB >> 8324912

Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers.

R D Gordon1, M D Ziesak, T J Tunny, M Stowasser, S A Klemm.   

Abstract

1. Six (12%) out of 52 respondents to newspaper advertisements for antihypertensive drug trials had elevated aldosterone to renin ratio, confirmed by repeated measurement. 2. Failure to suppress aldosterone with fludrocortisone acetate administration and oral salt loading confirmed the presence of primary aldosteronism in all six patients. 3. Two of the six patients have already had aldosterone-producing adenomas removed, one has commenced spironolactone, and one has an adrenal mass on computerized tomography but investigation is incomplete. 4. None of the six patients with primary aldosteronism had unprovoked hypokalaemia. 5. Plasma aldosterone levels did not distinguish those patients with subsequently proven primary aldosteronism from the others. Plasma renin activity (PRA) was a better discriminator, but not as good as the aldosterone to renin ratio. 6. The incidence of primary aldosteronism is probably much higher than the 1% currently quoted in texts, with earlier, normokalaemic forms accounting for the majority of cases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324912     DOI: 10.1111/j.1440-1681.1993.tb01687.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  20 in total

Review 1.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

Review 4.  Resistant hypertension and aldosteronism.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 5.  Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.

Authors:  Mohammed I Danjuma; Ipshita Mukherjee; Janine Makaronidis; Serge Osula
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

6.  The role of aldosteronism in causing obesity-related cardiovascular risk.

Authors:  David A Calhoun; Kumar Sharma
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

Review 7.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

Review 8.  Primary aldosteronism: diagnostic and therapeutic considerations.

Authors:  Mari K Nishizaka; David A Calhoun
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

9.  Familial mineralocorticoid induced hypertension in the sultanate of oman.

Authors:  Nicholas Jy Woodhouse; Omayma T Elshafie; Fatma Ben Abid; Suhail A Doi
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

Review 10.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.